Investors

Corporate Profile

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.

The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital ... More >>

Stock Quote

CSII (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$38.66
Change (%) Stock is Down 0.38 (0.97%)
Volume232,232
Data as of 04/01/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Upcoming Events

More >>
There are currently no events scheduled.

Recent News

More >>
03/04/15
Cardiovascular Systems to Present at Barclays 2015 Global Healthcare Conference
ST. PAUL, Minn.--(BUSINESS WIRE)--Mar. 4, 2015-- On Wednesday, March 11, 2015, Cardiovascular Systems’ (NASDAQ: CSII) President and Chief Executive Officer, David L. Martin, will present at the Barclays 2015 Global Healthcare Conference at 9:15 a.m. Eastern Time. You may access the live audio webcast and presentation materials in the Investors section at: http://www.csi360.com. Presentation materials also will be archived on CSI’s website. ... 
02/23/15
Modification of Atherosclerotic Plaque with Diamondback 360 Orbital Atherectomy Device Improved Drug Uptake in Peripheral Arteries in a Preclinical Study
ST. PAUL, Minn. & WASHINGTON--(BUSINESS WIRE)--Feb. 23, 2015-- Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), today announced that CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, disclosed that modification of atherosclerotic plaque with CSI’s Diamondback 360® orbital atherectomy device improved paclitaxel absorption by 50 percent in calcified cadavaric periph... 
02/23/15
Cardiovascular Systems Releases Two-Year ORBIT II Coronary Data in Late-Breaking Presentation at 2015 Cardiovascular Research Technologies Conference
Diamondback 360® Coronary Orbital Atherectomy System demonstrated: Long term durable outcomes for treating severely calcified lesions Low MACE rates including TLR and TVR ST. PAUL, Minn., & WASHINGTON--(BUSINESS WIRE)--Feb. 23, 2015-- Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), released two-year data from its ORBIT II study of the c... 
02/18/15
Cardiovascular Systems to Present ORBIT II Two-Year Coronary Data at 2015 Cardiovascular Research Technologies Conference
ST. PAUL, Minn. & WASHINGTON--(BUSINESS WIRE)--Feb. 18, 2015-- Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), will release two-year data from its ORBIT II study of the company’s Diamondback 360® Coronary Orbital Atherectomy System (OAS) in treating severely calcified lesions at the 2015 Cardiovascular Research Technologies (CRT) conference in Washington, D.C., Feb. 21-24, 2015. The pivotal ORBIT II study evaluated the safety and effectiveness ... 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.